Alzheimer's and Parkinson's disease therapies in the clinic

Chopade, Puja; Chopade, Neha; Zhao, Zongmin; Mitragotri, Samir; Liao, Rick; Suja, Vineeth Chandran

doi:10.1002/btm2.10367

Cited by 70 publications

(35 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The neuropathology of this ailment is distinguished by dopaminergic neuron death in the substantia nigra, neuroinflammation, and by the occurrence of Lewy bodies and Lewy neurites induced by α-syn aggregation [ 107 ]. PD patients manifest motor symptoms, including bradykinesia, tremor, postural instability, and rigidity, as well as non-motor symptoms, involving sleep disorders, sensory disorders, cognitive impairment, psychotic symptoms, and mood disturbances [ 108 ]. Currently, there are no treatments for patients suffering from PD and other synucleinopathies, and the majority of existing therapies are aimed at providing symptomatic relief in order to improve the patient’s quality of life [ 109 , 110 ].…”

Section: Progress On Plant-based Vaccines For Parkinson’s Diseasementioning

confidence: 99%

Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases

et al. 2023

View full text Add to dashboard Cite

Neurodegenerative diseases (NDDs) are characterized by the progressive degeneration and/or loss of neurons belonging to the central nervous system, and represent one of the major global health issues. Therefore, a number of immunotherapeutic approaches targeting the non-functional or toxic proteins that induce neurodegeneration in NDDs have been designed in the last decades. In this context, due to unprecedented advances in genetic engineering techniques and molecular farming technology, pioneering plant-based immunogenic antigen expression systems have been developed aiming to offer reliable alternatives to deal with important NDDs, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. Diverse reports have evidenced that plant-made vaccines trigger significant immune responses in model animals, supported by the production of antibodies against the aberrant proteins expressed in the aforementioned NDDs. Moreover, these immunogenic tools have various advantages that make them a viable alternative for preventing and treating NDDs, such as high scalability, no risk of contamination with human pathogens, cold chain free production, and lower production costs. Hence, this article presents an overview of the current progress on plant-manufactured vaccines for NDDs and discusses its future prospects.

show abstract

Section: Progress On Plant-based Vaccines For Parkinson’s Diseasementioning

confidence: 99%

Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases

et al. 2023

View full text Add to dashboard Cite

show abstract

“…While these drugs can often provide temporary relief of symptoms and sometimes slow the rate of cognitive or motor decline, they are unfortunately not curative and do not significantly alter the disease progression. Thus, these medications, although important, serve more as palliative treatments rather than definitive solutions [170][171][172][173]. This current state of therapeutic options emphasizes the need for more research into targeted treatments, particularly as we expand our understanding of the role that glutamate receptors play in the pathophysiology of AD and PD.…”

Section: Current Pharmacological Treatments For Alzheimer's and Parki...mentioning

confidence: 99%

Glutamate Receptor Dysregulation and Platelet Glutamate Dynamics in Alzheimer’s and Parkinson’s Diseases: Insights into Current Medications

Gautam,

Naik,

Naik

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Two of the most prevalent neurodegenerative disorders (NDDs), Alzheimer’s disease (AD) and Parkinson’s disease (PD), present significant challenges to healthcare systems worldwide. While the etiologies of AD and PD differ, both diseases share commonalities in synaptic dysfunction, thereby focusing attention on the role of neurotransmitters. The possible functions that platelets may play in neurodegenerative illnesses including PD and AD are becoming more acknowledged. In AD, platelets have been investigated for their ability to generate amyloid-ß (Aß) peptides, contributing to the formation of neurotoxic plaques. Moreover, platelets are considered biomarkers for early AD diagnosis. In PD, platelets have been studied for their involvement in oxidative stress and mitochondrial dysfunction, which are key factors in the disease’s pathogenesis. Emerging research shows that platelets, which release glutamate upon activation, also play a role in these disorders. Decreased glutamate uptake in platelets has been observed in Alzheimer’s and Parkinson’s patients, pointing to a systemic dysfunction in glutamate handling. This paper aims to elucidate the critical role that glutamate receptors play in the pathophysiology of both AD and PD. Utilizing data from clinical trials, animal models, and cellular studies, we reviewed how glutamate receptors dysfunction contributes to neurodegenerative (ND) processes such as excitotoxicity, synaptic loss, and cognitive impairment. The paper also reviews all current medications including glutamate receptor antagonists for AD and PD, highlighting their mode of action and limitations. A deeper understanding of glutamate receptor involvement including its systemic regulation by platelets could open new avenues for more effective treatments, potentially slowing disease progression and improving patient outcomes.

show abstract

“…Currently available pharmaceutical treatments provide only symptomatic relief or their effectiveness is contentious (Chopade et al , 2022). Psychological and occupational therapies are common nonpharmacological treatment approaches, but their clinical significance is also disputable (Zucchella et al , 2018).…”

Section: Introductionmentioning

confidence: 99%

From consumer values to attributes of natural health products for concentration and cognition: insights from a means-end-chain study

Wolf,

Emberger-Klein,

Menrad

2023

IJPHM

View full text Add to dashboard Cite

Purpose This paper aims to determine, which values guide consumers decision-making on natural health products for concentration and cognition (NHPCC) and how they link to choice-relevant product attributes. The purpose is to contribute to a better understanding of NHPCC consumption choices, which can encourage more consumer-centric product development and positioning. Design/methodology/approach Based on the means-end chain approach, in-depth laddering interviews with 26 consumers of NHP were conducted in Germany from October to December 2020. Qualitative content analysis was applied and a hierarchical value map over the dominant association was built and analyzed. Findings Five terminal values were found to be relevant for NHPCC decision-making. The personal focused values security, self-direction and stimulation are via health mainly associated with trust and a conscious decision-making, which is linked to the product attributes of effectiveness, tolerance and declaration. Social focused values of universalism or benevolence guide attention on the attributes of sustainability and regionality. Originality/value The study contributes to close the knowledge gap concerning the linkages between abstract values and concrete product attributes of NHP through associated consequences. To the best of the authors’ knowledge, this is the first study that analyzed these links for NHPCC, although such products are gaining more interest among companies and consumers. Companies can benefit from the outcomes by developing more consumer-centric product concepts and marketing communication strategies for NHPCC. Due to higher attention on relevant information, consumers’ decision-making could become safer and more conscious.

show abstract

Alzheimer's and Parkinson's disease therapies in the clinic

Cited by 70 publications

References 148 publications

Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases

Current Advances of Plant-Based Vaccines for Neurodegenerative Diseases

Glutamate Receptor Dysregulation and Platelet Glutamate Dynamics in Alzheimer’s and Parkinson’s Diseases: Insights into Current Medications

From consumer values to attributes of natural health products for concentration and cognition: insights from a means-end-chain study

Contact Info

Product

Resources

About